{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:17Z","timestamp":1793320637492,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11136-022-03181-4","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T07:02:48Z","timestamp":1657350168000},"page":"1247-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-708X","authenticated-orcid":false,"given":"Kim","family":"Cocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"issue":"235","key":"3181_CR1","first-page":"65132","volume":"74","author":"Food and Durg Administration","year":"2009","unstructured":"Food and Durg Administration. (2009). Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register, 74(235), 65132\u201365133.","journal-title":"Federal Register"},{"issue":"1","key":"3181_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","volume":"24","author":"A Anota","year":"2015","unstructured":"Anota, A., Hamidou, Z., Paget-Bailly, S., et al. (2015). Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research, 24(1), 5\u201318.","journal-title":"Quality of Life Research"},{"issue":"4","key":"3181_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407\u2013415.","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"3181_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1475-6773.2005.0l374.x","volume":"40","author":"KW Wyrwich","year":"2005","unstructured":"Wyrwich, K. W., Tierney, W. M., Babu, A. N., Kroenke, K., & Wolinsky, F. D. (2005). A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research, 40(2), 577\u2013592.","journal-title":"Health Services Research"},{"issue":"7","key":"3181_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1023\/A:1013138911638","volume":"10","author":"H Beckerman","year":"2001","unstructured":"Beckerman, H., Roebroeck, M. E., Lankhorst, G. J., Becher, J. G., Bezemer, P. D., & Verbeek, A. L. (2001). Smallest real difference, a link between reproducibility and responsiveness. Quality of Life Research., 10(7), 571\u2013578.","journal-title":"Quality of Life Research."},{"issue":"5","key":"3181_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute., 85(5), 365\u2013376.","journal-title":"Journal of the National Cancer Institute."},{"key":"3181_CR7","volume-title":"The EORTC QLQ-C30 scoring manual","author":"P Fayers","year":"2001","unstructured":"Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). European Organization for Research and Treatment of Cancer.","edition":"3"},{"key":"3181_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.clcc.2019.08.005","volume":"18","author":"H-J Lenz","year":"2019","unstructured":"Lenz, H.-J., Argiles, G., Yoshino, T., et al. (2019). Health-related quality of life in the Phase III LUME-Colon 1 study: Comparison and interpretation of results from EORTC QLQ-C30 analyses. Clinical Colorectal Cancer, 18, 269\u2013279.","journal-title":"Clinical Colorectal Cancer"},{"issue":"5","key":"3181_CR9","doi-asserted-by":"publisher","first-page":"e0125350","DOI":"10.1371\/journal.pone.0125350","volume":"10","author":"A Anota","year":"2015","unstructured":"Anota, A., Mouillet, G., Trouilloud, I., et al. (2015). Sequential FOLFIRI 3+ Gemcitabine improves health-related quality of life deterioration-free survival of patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. PLoS ONE, 10(5), e0125350.","journal-title":"PLoS ONE"},{"issue":"13","key":"3181_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","volume":"32","author":"MR Stockler","year":"2014","unstructured":"Stockler, M. R., Hilpert, F., Friedlander, M., et al. (2014). Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology., 32(13), 1309.","journal-title":"Journal of Clinical Oncology."},{"issue":"2","key":"3181_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12375","volume":"162","author":"CN Harrison","year":"2013","unstructured":"Harrison, C. N., Mesa, R. A., Kiladjian, J. J., et al. (2013). Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 162(2), 229\u2013239.","journal-title":"British Journal of Haematology"},{"issue":"15","key":"3181_CR12","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","volume":"46","author":"F Bonnetain","year":"2010","unstructured":"Bonnetain, F., Dahan, L., Maillard, E., et al. (2010). Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer., 46(15), 2753\u20132762.","journal-title":"European Journal of Cancer."},{"key":"3181_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/jco.2015.33.7_suppl.287","volume":"33","author":"A Eisenhardt","year":"2015","unstructured":"Eisenhardt, A., Schneider, T., Scheithe, K., Colling, C., & Heidenreich, A. (2015). Health-related quality of life in patients with advanced prostate cancer undergoing treatment with TRIPTOrelin Pamoate SIX month formulation: Results of the non-interventional TRIPTOSIX study. Journal of Clinical Oncology, 33, 287.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"3181_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","volume":"41","author":"D Osoba","year":"2005","unstructured":"Osoba, D., Bezjak, A., Brundage, M., et al. (2005). Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer., 41(2), 280\u2013287.","journal-title":"European Journal of Cancer."},{"key":"3181_CR15","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1111\/j.1524-4733.2007.00278.x","volume":"10","author":"D Osoba","year":"2007","unstructured":"Osoba, D., Bezjak, A., Brundage, M., Pater, J., National Cancer Institute of Canada Clinical Trials Group. (2007). Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value Health., 10, S138\u2013S145.","journal-title":"Value Health."},{"issue":"32","key":"3181_CR16","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1200\/JCO.2007.11.4645","volume":"25","author":"M Brundage","year":"2007","unstructured":"Brundage, M., Osoba, D., Bezjak, A., Tu, D., Palmer, M., & Pater, J. (2007). Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology., 25(32), 5078\u20135081.","journal-title":"Journal of Clinical Oncology."},{"issue":"2","key":"3181_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000484142","volume":"94","author":"T Kawahara","year":"2018","unstructured":"Kawahara, T., Shimozuma, K., Shiroiwa, T., et al. (2018). Patient-reported outcome results from the open-label randomized phase III select bc trial evaluating first-line s-1 therapy for metastatic breast cancer. Oncology, 94(2), 107\u2013115.","journal-title":"Oncology"},{"issue":"1","key":"3181_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology., 29(1), 89\u201396.","journal-title":"Journal of Clinical Oncology."},{"key":"3181_CR19","unstructured":"SF-36 scoring. Retrieved from https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form\/scoring.html."},{"issue":"5","key":"3181_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/ejh.13316","volume":"103","author":"K Sully","year":"2019","unstructured":"Sully, K., Trigg, A., Bonner, N., Moreno-Koehler, A., Trennery, C., Shah, N., Yucel, E., Panjabi, S., & Cocks, K. (2019). Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. European Journal of Haematology, 103(5), 500\u2013509. https:\/\/doi.org\/10.1111\/ejh.13316","journal-title":"European Journal of Haematology"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-022-03181-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T04:02:07Z","timestamp":1682222527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-022-03181-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3181"],"URL":"https:\/\/doi.org\/10.1007\/s11136-022-03181-4","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"18 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JB was an employee of Amgen, Inc. and owns Amgen stock. Amgen is a commercial organisation that sponsors clinical trials. KC is a statistical consultant and received funding from Amgen, Inc. for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}